Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Dec 14;13:1117936. doi: 10.3389/fphar.2022.1117936

Corrigendum: Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases

Jianglei Li 1,2, Meihong Yu 1,2, Shifeng Fu 1,2, Deliang Liu 1,2,*, Yuyong Tan 1,2,*
PMCID: PMC9795403  PMID: 36588693

In the published article, there was an error in the Funding statement. “This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and Graduate Research Innovation Project of Central South University.” The correct Funding statement appears below.

Funding

This work was supported by Scientific research project of Hunan Provincial Health Commission (No. 202103030980) and the Fundamental Research Funds for the Central Universities of Central South University (No. 2022ZZTS0860)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES